Health Care • Industrial Specialties
$153.71 ▲ +0.09
(+0.06%)
MKT CAP: $10.92B • VOL: 2.01M
52W L $130 52W H $200
ALGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.03B | $4.00B | $3.86B |
| YoY Revenue Growth % | +0.9% | +3.5% | — |
| Gross Profit | $2.71B | $2.80B | $1.70B |
| Gross Margin % | 67.2% | 70.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $545.8M | $607.6M | $643.3M |
| Operating Margin % | 13.5% | 15.2% | 16.7% |
| Net Income (GAAP) | $410.0M | $421.0M | $445.0M |
| EBITDA (Normalized) | $627.7M | $700.1M | $782.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $593.2M | $738.2M | $785.8M |
| Capital Expenditures (CapEx) | $102.4M | $115.6M | $173.8M |
| Free Cash Flow (FCF) | $490.8M | $622.7M | $612.0M |
| FCF Margin % | 12.2% | 15.6% | 15.8% |
| Return on Invested Capital (ROIC %) | 11.0% | 12.4% | 14.0% |
| Cash & Short-Term Equivalents | $1.09B | $1.04B | $660.6M |
| Total Debt (Short + Long Term) | $983.0M | $1.06B | $1.41B |
| Total Stockholders' Equity | $4.05B | $3.85B | $2.88B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALGN.